Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2025BMJ OpenOpen Access

Risk of hepatitis B virus reactivation associated with interleukin inhibitor therapies: protocol for a systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMarouf Mouhammad AlhalabiHAHussam Aldeen Alshiekh

Discussion

Loading...

Member takes

Overview

Systematic review and meta-analysis assess hepatitis B virus reactivation in patients on interleukin inhibitor therapies, suggesting potential publication bias.

Key Points

  • This review aims to quantify the risk of hepatitis B virus reactivation associated with interleukin inhibitor therapies.
  • Follow PRISMA guidelines for systematic reviews and meta-analyses.
  • Conduct a comprehensive search in multiple databases including MEDLINE and PubMed.
  • Estimate HBVr rates using a generalised linear mixed model with random-effects models to account for variability.
  • Perform sensitivity analyses to evaluate robustness and assess heterogeneity with I² and Cochran’s Q.
  • Evaluate publication bias using Doi plots and Luis Furuya-Kanamori index.
  • Identified potential risk of hepatitis B virus reactivation in patients using interleukin inhibitors.
  • Highlighted inconsistencies in current research regarding HBVr rates.
  • Sensitivity analyses reveal robust findings across various study characteristics.

Cite This Study

Alhalabi et al. (2025) studied this question.

synapsesocial.com/papers/69254362c0ce034ddc3581a4https://doi.org/10.1136/bmjopen-2024-098671
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hepatitis B reactivation with TNF-α inhibitors: assessing antiviral prophylaxis efficacy — protocol for systematic review and meta-analysis2025 · 1 citations
  2. 2Hepatitis B Virus Reactivation Risk With <scp>IL</scp> ‐17, <scp>IL</scp> ‐23/ <scp>IL</scp> ‐12, or <scp>JAK</scp> Inhibitors: A Systematic Review and Meta‐Analysis2026
  3. 3TNF‐α Inhibitors and HBV Reactivation Risk in HBsAg−/Anti‐HBc+ Patients: A Systematic Review and Meta‐Analysis2026
  4. 4Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents2026 · 1 citations
  5. 5Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer2025 · 8 citations